Nimesh A Patel, Luis A Acaba-Berrocal, Sandra Hoyek, Celine Chaaya, Kenneth C Fan, Maria Ana Martinez-Castellanos, Caroline R Baumal, C Armitage Harper, Audina M Berrocal
{"title":"玻璃体内注射抗vegf治疗ROP后的美国和非美国再治疗率。","authors":"Nimesh A Patel, Luis A Acaba-Berrocal, Sandra Hoyek, Celine Chaaya, Kenneth C Fan, Maria Ana Martinez-Castellanos, Caroline R Baumal, C Armitage Harper, Audina M Berrocal","doi":"10.1016/j.oret.2025.03.013","DOIUrl":null,"url":null,"abstract":"<p><p>This multicenter study determines the differences in retreatment rates after intravitreal anti-VEGF treatment for Retinopathy of Prematurity between the United States (US) and non-US sites. Ranibizumab was associated with significantly more retreatment compared to bevacizumab.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"US vs non-US Retreatment Rates After Intravitreal Anti-VEGF Injections for ROP.\",\"authors\":\"Nimesh A Patel, Luis A Acaba-Berrocal, Sandra Hoyek, Celine Chaaya, Kenneth C Fan, Maria Ana Martinez-Castellanos, Caroline R Baumal, C Armitage Harper, Audina M Berrocal\",\"doi\":\"10.1016/j.oret.2025.03.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This multicenter study determines the differences in retreatment rates after intravitreal anti-VEGF treatment for Retinopathy of Prematurity between the United States (US) and non-US sites. Ranibizumab was associated with significantly more retreatment compared to bevacizumab.</p>\",\"PeriodicalId\":19501,\"journal\":{\"name\":\"Ophthalmology. Retina\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-03-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology. Retina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.oret.2025.03.013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oret.2025.03.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
US vs non-US Retreatment Rates After Intravitreal Anti-VEGF Injections for ROP.
This multicenter study determines the differences in retreatment rates after intravitreal anti-VEGF treatment for Retinopathy of Prematurity between the United States (US) and non-US sites. Ranibizumab was associated with significantly more retreatment compared to bevacizumab.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
